|
Since 2002, Dr. Graves has been President and CEO of Santen Inc., a wholly owned subsidiary of Japan's Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4536). She joined Santen Inc. in 1995 as Vice President of Clinical Affairs to initiate the company's clinical development in the U.S. Under her leadership, Santen's research and development team successfully developed and obtained U.S. Food and Drug Administration ("FDA") approval for three ophthalmic products in major therapeutic areas. Santen's U.S. products are now marketed by Johnson & Johnson Vision Care. Prior to joining Santen Inc., Dr. Graves spent nine years with Alcon Laboratories, Inc. (NYSE:ACL), beginning in 1986 as a Senior Scientist. In 1991, she received Alcon's Technical Excellence Award and, as her research progressed, was named Associate Director of Alcon's Clinical Science Division in 1992 and then Director of International Ophthalmology in 1993. Dr. Graves is the author of over 30 research papers. She is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society, and Women in Ophthalmology. In addition, Dr. Graves co-founded Ophthalmic Women Leaders with Dr. Marguerite McDonald. | 